Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: HTDS - Hard To Treat Diseases

14 Aug 2009 06:24 AM

12 Aug 2009 10:46 AM

31 Aug 2006 11:41 AM <--

29 Jun 2005 01:23 AM

28 Jun 2005 09:27 PM

02 Jun 2005 05:44 AM

Return to HTDS - Hard To Treat Diseases

Hard To Treat Diseases (Pink: HTDS): holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating Cancer and Rheumatoid Arthritis under medical patent (US Patent 6,274,356). The Company is focused on developing alliances with established, well-financed strategic partners to effectively manufacture, distribute and market Tubercin internationally. It is a new or additive weapon in the cocktail required to fight cancer and other diseases - like AIDS.
Website: htdsotc.com ...........RB chatter: ragingbull.lycos.com